A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection. (October 2017)

• Record Type: Journal Article
• Authors: Zhang, Yingjie; Yin, Jiechao; Li, Tianhe; Zhou, Bing; Xu, Pengfei; Che, Ruixiang; Liu, Yunye; Cao, Hongxue; Ye, Xianlong; Yang, Yongbi; Qi, Xiaole; Zheng, Shimin; Ding, Guojie; Ren, Guiping; Yang, Hanchun; Wang, Xiaomei; Li, Deshan
• Is Part Of: Research in veterinary science. Volume 114(2017)
• Page Start: 194
• Page End: 201
• Publication Date: 2017-10
• Subjects: recombinant avian antibody -- IBDV -- neutralization activity -- therapeutic efficacy; Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; Médecine vétérinaire -- Périodiques; Médecine vétérinaire -- Recherche -- Périodiques; Diergeneeskunde; 636.089
• DOI: 10.1016/j.rvsc.2017.04.003
• Languages: English
• ISSNs: 0034-5288

Abstract

Abstract: A stable cell-line was established that expressed the recombinant avian antibody (rAb) against the infectious bursal disease virus (IBDV). rAb exhibited neutralization activity to IBDV-B87 strain in DF1 cells. The minimum rAb concentration required for inhibition of the cytopathic effect (CPE) was 1.563 μg/mL. To test the efficacy of rAb, a 168-h cohabitation challenge experiment was performed to transmit the disease from the chickens challenged with vvIBDV (HLJ0504 strain) to three test groups of chickens, i.e. (1) chickens treated with rAb, (2) chickens treated with yolk antibody, and (3) non-treatment chickens. The survival rates of chickens treated with rAb, yolk antibody and without treatment were 73%, 67% and 20%, respectively. Another batch of chickens was challenged with IBDV (BC6/85 strain) and then injected with rAb (1.0 mg/kg) 6, 24 and 36 h post-challenge. Non-treatment chickens had 100% morbidity, whereas those administered with rAb exhibited only 20% morbidity. Morbidity was evaluated using clinical indicators and bursal histopathological section. This study provides a new approach to treating IBDV and the rAb represents a promising candidate for this IBDV therapy. Highlights: A stable cell line expressing recombinant avian antibody against IBDV was established. Recombinant avian antibody exhibited neutralization activity to IBDV-B87 strain in DF1 cells. Recombinant avian antibody exhibited good efficacy in treatment of IBD.